Let's make poor reporting of early phase dose finding clinical trials a thing of the past
In 2017, I was drafting the first manuscript for a phase I clinical trial. I was familiar with the consolidated standards of reporting trials (Consort) for randomised parallel group trials, so I was surprised by the absence of Consort reporting guidance tailored for early phase dose finding trials. After searching top medical journals for published dose finding trials to assess how they had been reported, I found huge variation in what was being reported and their quality. This presented some big problems for medical research—poor reporting in clinical trials jeopardises patient safety, erod...
Source: bmj.com